Open AccessPTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma
Author(s) -
Antonio Dono,
Sonali Mitra,
Mauli Shah,
Takeshi Takayasu,
JayJiguang Zhu,
Nitin Tandon,
Chirag B. Patel,
Yoshua Esquenazi,
Leomar Y. Ballester
Publication year - 2021
Publication title -
journal of neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.256
H-Index - 114
eISSN - 1573-7373
pISSN - 0167-594X
DOI - 10.1007/s11060-021-03755-1
Subject(s) - pten , medicine , oncology , idh1 , glioblastoma , cancer , isocitrate dehydrogenase , cancer research , mutant , gene , apoptosis , biology , pi3k/akt/mtor pathway , biochemistry , enzyme
Optimal treatment for recurrent glioblastoma isocitrate dehydrogenase 1 and 2 wild-type (rGBM IDH-WT) is not standardized, resulting in multiple therapeutic approaches. A phase III clinical trial showed that tumor treating fields (TTFields) monotherapy provided comparable survival benefits to physician's chemotherapy choice in rGBM. However, patients did not equally benefit from TTFields, highlighting the importance of identifying predictive biomarkers of TTFields efficacy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom